Docoh
Loading...

CVAC CureVac

Filed: 16 Nov 20, 1:10pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2020

 

Commission File Number 001-39446

  

 

 

CureVac N.V.

  

 

 

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive offices)

  

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

FORM 20-F  x         FORM 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

 

YES  ¨          NO  x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

 

 

 

 

 

On November 16, 2020, CureVac N.V. (the “Company”) issued a press release reporting that the European Commission has announced that on November 17, 2020, it will authorize an Advanced Purchase Agreement with the Company for the supply of up to 405 million doses of mRNA-Based COVID-19 vaccine candidate, CVnCoV. The press release is attached hereto as Exhibit 99.1.

 

The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 CUREVAC N.V.
   
 By:  /s/ Franz-Werner Haas, LLD, LLM 
  Chief Executive Officer

 

Date: November 16, 2020

 

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT NO. DESCRIPTION
99.1 CureVac N.V. Press Release dated November 16, 2020.